Organization
Institut Paoli-Calmettes, Marseille, France
22 abstracts
3 posters
Abstract
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,
Abstract
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Org: City of Hope National Medical Center, Erasmus University Medical Center, Institut Paoli-Calmettes, Marseille, France, University Medical Center Groningen, MD Anderson Cancer Center,
Abstract
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.Org: PACAN platform, Unité d'Oncogériatrie, Department of Geriatrics, Institut Paoli-Calmettes, Marseille, France, Institut Curie, Saint Cloud, France,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,
Abstract
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine and Fred Hutchinson Cancer Center, University of Pittsburgh, Washington University School of Medicine, Kaplan Hospital,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Abstract
Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Centre Leon Berard, Lyon I University, Lyon, France, IUCT-Oncopole Toulouse,
Abstract
First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study.Org: Department of Medical Oncology, Institute Bergonié Cancer Center, Bordeaux, France, Department of Radiation Oncology, Institut Bergonie, Bordeaux, France, Institut Paoli-Calmettes, Marseille, France, Early clinical unit CLIP2 INCA, Centre GF LECLERC, Dijon, France, Medical oncology Department, Institut Bergonié, Bordeaux, France,
Abstract
Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.Org: Centre Leon Berard, Lyon I University, Hôpital Européen Georges Pompidou, Sorbonne University and Saint-Antoine Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.Org: Cancer Research Center of Marseille (CRCM), Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone,
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.Org: Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Cliniques Universitaires Saint-Luc, Department of Gastroenterology, Division of Digestive Oncology, Centre Léon Bérard,
Abstract
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone, Marseille, France, Institut Universitaire du Cancer Toulouse, Toulouse, France,
Abstract
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.Org: Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France, Institut Gustave Roussy, Villejuif, France, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,
Abstract
Comparison of generic and specific anxiety in patients treated with apalutamide plus active surveillance vs active surveillance alone for low and intermediate risk prostate cancer.Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille Universite, CRCM, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, IRD,
Abstract
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.Org: Centre Léon-Bérard, Centre Léon Bérard, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis,
Abstract
Early palliative care for patients with metastatic upper gastrointestinal cancers: A survival analysis of the EPIC randomized trial.Org: Institut du Cancer de Montpellier, Centre Oscar Lambret, Institut de Cancérologie de l'Ouest, Angers, France, Digestive Oncology, Hopital Duchenne, Medical Oncology Department, Lille University Hospital, University of Lille, Lille, France,
Abstract
Results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.Org: Institut Paoli-Calmettes, Marseille, France, Paoli-Calmettes Institute, Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.Org: Université Paris Cité, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Hôpital Bichat Claude Bernard, AP-HP.Nord, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,